Ghent, Belgium, 27 January 2022 - V-Bio Ventures, a venture capital company that focuses specifically on the segment of young pioneering biotech companies, has increased the capital of its second fund V-Bio Fund 2 to 96 million euros. The fundraising will continue for several months, and the fund managers expect the target of EUR 100 million will be achieved.
In recent public discussions on economic progress, people have been asking: is infinite growth really the best way to measure economic success? With a background in biology, having entered the investment world in the year 2000, Christina Takke found this an intriguing question best viewed through the metaphor of life in a test tube versus a real ecosystem.
Ghent, Belgium, 20 January 2022 – Dr. Ann Van Gysel has been appointed as CEO of the flanders.healthTech spearhead cluster. She will lead the cluster, which brings together personalized and digital medicine and healthcare technology in Flanders, and supports the development and implementation of new technologies in the Flemish healthcare sector.
Mechelen, Belgium, January 25, 2022 - Belgian company ElmediX is developing intensive and controlled heat treatments for the treatment of cancer. A new capital injection of 4M euros brings the total to almost 12M euros (including VLAIO research grants worth 1.8M euros) and accelerates the trajectory of this innovative MedTech company.
As part of the ‘Health & Biotech Valley of Tomorrow’ initiative, the Belgian government recently signed a charter together with stakeholders from academia and industry, pledging to cement Belgium’s status as a biotech powerhouse in the next 10 to 20 years. Over the next few months, working groups will translate recommendations of a consultancy report into a concrete strategic plan for the future of the country. Amongst other topics, experts will evaluate ways to encourage more collaboration, provide financial stimuli, and make better use of health data.
Long COVID is a less talked-about aspect of the COVID-19 pandemic, yet its impact on society is already profound. Although this problem is still largely flying under the radar of the life sciences industry, a couple of first movers have already initiated clinical programs to address the condition. If more companies move into this space, long COVID may prove a catalyst for R&D in other related and underserved indications, like chronic fatigue syndrome.
Long COVID is a less talked-about aspect of the COVID-19 pandemic, yet its impact on society is already profound. Although this problem is still largely flying under the radar of the life sciences industry, a couple of first movers have already initiated clinical programs to address the condition. If more companies move into this space, long COVID may prove a catalyst for R&D in other related and underserved indications, like chronic fatigue syndrome.
Ghent, Belgium, 9 December 2021 – Corteria Pharmaceuticals, a French biotechnology company specialized in the development of interceptive therapies for heart failure subpopulations, today announced the successful completion of its Seed round, providing EUR 12 million to pursue the development of a series of programs in-licensed from Sanofi S.A. (Paris, France). The seed round was led by Kurma Partners and includes V-Bio Ventures, Omnes Capital, and InVivo Capital. As part of the financing, Thierry Laugel (Chair) and Peter Neubeck from Kurma Partners, Ward Capoen from V-Bio Ventures, Claire Poulard from Omnes Capital, and Luis Pareras from InVivo Capital Health will join the Board of Directors.
Ghent, Belgium, 27 January 2022 - V-Bio Ventures, a venture capital company that focuses specifically on the segment of young pioneering biotech companies, has increased the capital of its second fund V-Bio Fund 2 to 96 million euros. The fundraising will continue for several months, and the fund managers expect the target of EUR 100 million will be achieved.
In recent public discussions on economic progress, people have been asking: is infinite growth really the best way to measure economic success? With a background in biology, having entered the investment world in the year 2000, Christina Takke found this an intriguing question best viewed through the metaphor of life in a test tube versus a real ecosystem.
Ghent, Belgium, 20 January 2022 – Dr. Ann Van Gysel has been appointed as CEO of the flanders.healthTech spearhead cluster. She will lead the cluster, which brings together personalized and digital medicine and healthcare technology in Flanders, and supports the development and implementation of new technologies in the Flemish healthcare sector.
Mechelen, Belgium, January 25, 2022 - Belgian company ElmediX is developing intensive and controlled heat treatments for the treatment of cancer. A new capital injection of 4M euros brings the total to almost 12M euros (including VLAIO research grants worth 1.8M euros) and accelerates the trajectory of this innovative MedTech company.
As part of the ‘Health & Biotech Valley of Tomorrow’ initiative, the Belgian government recently signed a charter together with stakeholders from academia and industry, pledging to cement Belgium’s status as a biotech powerhouse in the next 10 to 20 years. Over the next few months, working groups will translate recommendations of a consultancy report into a concrete strategic plan for the future of the country. Amongst other topics, experts will evaluate ways to encourage more collaboration, provide financial stimuli, and make better use of health data.
Long COVID is a less talked-about aspect of the COVID-19 pandemic, yet its impact on society is already profound. Although this problem is still largely flying under the radar of the life sciences industry, a couple of first movers have already initiated clinical programs to address the condition. If more companies move into this space, long COVID may prove a catalyst for R&D in other related and underserved indications, like chronic fatigue syndrome.
Long COVID is a less talked-about aspect of the COVID-19 pandemic, yet its impact on society is already profound. Although this problem is still largely flying under the radar of the life sciences industry, a couple of first movers have already initiated clinical programs to address the condition. If more companies move into this space, long COVID may prove a catalyst for R&D in other related and underserved indications, like chronic fatigue syndrome.
Ghent, Belgium, 9 December 2021 – Corteria Pharmaceuticals, a French biotechnology company specialized in the development of interceptive therapies for heart failure subpopulations, today announced the successful completion of its Seed round, providing EUR 12 million to pursue the development of a series of programs in-licensed from Sanofi S.A. (Paris, France). The seed round was led by Kurma Partners and includes V-Bio Ventures, Omnes Capital, and InVivo Capital. As part of the financing, Thierry Laugel (Chair) and Peter Neubeck from Kurma Partners, Ward Capoen from V-Bio Ventures, Claire Poulard from Omnes Capital, and Luis Pareras from InVivo Capital Health will join the Board of Directors.